【摘要】：目的:本實驗通過研究觀察芪樓固腎方對膜性腎病大鼠尿蛋白、血清生化指標、腎臟病理以及腎組織Nephrin mRNA、Podocin mRNA表達的影響,探討芪樓固腎方治療膜性腎病的作用機制。方法:選取50只雄性Wistar大鼠,隨機取10只作為空白組,其余大鼠預免疫一周后,隔日一次尾靜脈注射牛血清白蛋白(C-BSA),制備膜性腎病大鼠模型。模型制備成功后將剩余40只大鼠隨機分為4組,每組10只,即模型組、芪樓固腎方低劑量組、芪樓固腎方高劑量組、雷公藤多甙片組。動態(tài)觀察56天,檢測24小時尿蛋白定量(UTP)、血清總蛋白(TP)白蛋白(ALB)、肝功能(ALT、AST)的變化情況,通過光鏡、電鏡觀察腎組織的病理改變,并運用Real-time PCR法檢測腎組織Nephrin mRNA、Podocin mRNA的表達情況。結果:1.芪樓固腎方可改善膜性腎病大鼠的一般狀態(tài),減少尿蛋白,升高血清總蛋白和白蛋白,與模型對照組比較差異有統(tǒng)計學意義(P0.05,P0.01);其中芪樓固腎方低劑量組療效最佳;但對肝功能的影響無明顯改變,各組間差異無統(tǒng)計學意義(P0.05);2.芪樓固腎方可在一定程度上減輕膜性腎病大鼠腎臟的病理損傷,減少免疫復合物的沉積,抑制腎小球基底膜增厚;3.芪樓固腎方可上調膜性腎病大鼠腎組織Nephrin mRNA、Podocin mRNA的表達,與模型對照組比較差異有統(tǒng)計學意義(P0.01),以芪樓固腎方低劑量效果為佳;芪樓固腎方高劑量與雷公藤多甙片組比較,差異無統(tǒng)計學意義(P0.05)。結論:1芪樓固腎方能夠減少膜性腎病大鼠的蛋白尿,升高血清白蛋白,對膜性腎病大鼠具有一定的治療作用。2芪樓固腎方能夠在一定程度上減輕膜性腎病大鼠腎組織病理的損傷,延緩腎組織病理損傷的進展;3芪樓固腎方可上調膜性腎病大鼠腎組織中Nephrin mRNA、Podocin mRNA的表達,保護足細胞,維持足細胞裂孔膜結構和腎小球濾過屏障功能的完整性,從而減少尿蛋白的排出,延緩膜性腎病的進展。
[Abstract]:Objective: to investigate the effects of Qilou Gushen recipe on urine protein, serum biochemical index, renal pathology and Nephrin mRNA,Podocin mRNA expression in rats with membranous nephropathy (MNS), and to explore the mechanism of QLDSM in treating membranous nephropathy. Methods: fifty male Wistar rats were randomly selected as blank group. The other rats were injected with bovine serum albumin (C-BSA) once every other day after one week of preimmunization to establish the model of membranous nephropathy in rats. After the model was successfully prepared, the remaining 40 rats were randomly divided into 4 groups, 10 rats in each group, namely model group, low dose group, high dose group and Tripterygium wilfordii polyglycoside group. The changes of liver function (ALT,AST) of serum total protein (TP) albumin (ALB), (ALT,AST) in 24 hours urine protein quantitative (UTP), were observed dynamically for 56 days. The pathological changes of renal tissue were observed by light microscope and electron microscope. Real-time PCR method was used to detect the expression of Nephrin mRNA,Podocin mRNA in renal tissue. The result is 1: 1. QLU Gushen Fang improved the general state of membranous nephropathy rats, reduced urinary protein, increased serum total protein and albumin, compared with the model control group, the difference was statistically significant (P0.05, P0.01). Qilou Guishen prescription low dose group is the best, but the effect on liver function has no significant change, there is no significant difference between the groups (P0.05); 2. QLU Gushen decoction alleviates the pathological damage of kidney, reduces the deposition of immune complex, and inhibits the thickening of glomerular basement membrane to a certain extent in rats with membranous nephropathy. QLU Gushen Fang upregulated the expression of Nephrin mRNA,Podocin mRNA in renal tissue of membranous nephropathy rats compared with the model control group (P0.01). There was no significant difference between the high dose of QLU Gushen recipe and the Tripterygium wilfordii polyglycosides group (P0.05). Conclusion: 1 Qilou Gushen recipe can reduce proteinuria and increase serum albumin in membranous nephropathy rats. It has certain therapeutic effect on membranous nephropathy rats. 2 QLU Gu Shen Fang can alleviate the pathological damage of renal tissue to some extent and delay the progress of pathological injury of renal tissue in rats with membranous nephropathy. (3) QLU Gu Shen Fang upregulated the expression of Nephrin mRNA,Podocin mRNA in renal tissue of rats with membranous nephropathy, protected podocytes, and maintained the integrity of membrane structure and glomerular filtration barrier function of podocytes, so as to reduce the excretion of urinary protein. Delay the progression of membranous nephropathy.
【學位授予單位】：黑龍江省中醫(yī)藥科學院
【學位級別】：碩士
【學位授予年份】：2016
【分類號】：R277.5

【相似文獻】

相關期刊論文 前10條

1 余學清,楊瓊瓊;特發(fā)性膜性腎病的治療[J];中國實用內科雜志;2003年05期

2 周仲昊,朱蘊秋;膜性腎病的臨床病理與預后的關系[J];齊齊哈爾醫(yī)學院學報;2003年05期

3 王太華,李清初,于克波;足細胞與膜性腎病[J];中國中西醫(yī)結合腎病雜志;2004年06期

4 草X4哲郎 ,李勝;膜性腎病[J];日本醫(yī)學介紹;2005年09期

5 梁世凱;許菲菲;舒桂琴;呂吟秋;邵蓉蓉;劉毅;;70例特發(fā)性膜性腎病的臨床特點和治療探討[J];中國中西醫(yī)結合腎病雜志;2006年10期

6 朱虎章;;膜性腎病并發(fā)成人呼吸窘迫綜合征1例救治體會[J];中國中西醫(yī)結合腎病雜志;2007年03期

7 陳以平;鄧躍毅;;特發(fā)性膜性腎病[J];中國中西醫(yī)結合腎病雜志;2007年08期

8 舒桂琴;許菲菲;梁世凱;劉毅;呂吟秋;邵蓉蓉;;51例成人特發(fā)性膜性腎病的治療觀察[J];浙江預防醫(yī)學;2007年10期

9 何志軍;楊琪;周柱亮;;膜性腎病136例分析[J];人民軍醫(yī);2007年11期

10 黃少珍;唐德q，

本文編號：2318248